Eli Lilly (LLY)

1,042.90
+4.50 (0.43%)
NYSE · Last Trade: Jan 20th, 12:18 PM EST
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
AstraZeneca Signals End of an Era: Formal Move to NYSE Triggers Major Index Rebalancing
LONDON — January 20, 2026 — In a milestone moment for global capital markets, pharmaceutical giant AstraZeneca (NYSE: AZN) has officially filed its formal notice of voluntary withdrawal from the Nasdaq Stock Market today. The move marks the final countdown for one of the most significant listing migrations in recent history, as
Via MarketMinute · January 20, 2026
3 Biotech Stocks That Look Like “Sure-Fire” Winners in 2026marketbeat.com
Via MarketBeat · January 20, 2026
Prediction: This Healthcare Stock Could Soar by 72% in 2026fool.com
And the share price appreciation could happen pretty soon.
Via The Motley Fool · January 19, 2026
Down 55%, Should You Buy the Dip on Pfizer?fool.com
Pfizer's stock has started to turn higher, but it is still down massively; is now the time to jump aboard?
Via The Motley Fool · January 19, 2026
NVO Shares Rise On Strong Kickstart For Wegovy Pill In US: Retail Eyes Up To $110 As ‘Fair Value’stocktwits.com
Via Stocktwits · January 16, 2026
Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them Allmarketbeat.com
Via MarketBeat · January 19, 2026
Silicon Meets Science: NVIDIA and Eli Lilly Launch $1 Billion AI Lab to Engineer the Future of Medicine
In a move that signals a paradigm shift for the pharmaceutical industry, NVIDIA (NASDAQ: NVDA) and Eli Lilly and Company (NYSE: LLY) have announced the launch of a $1 billion joint AI co-innovation lab. Unveiled on January 12, 2026, during the opening of the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, this landmark [...]
Via TokenRing AI · January 19, 2026
The Best Healthcare Stocks to Buy With $5,000 in 2026 and Hold Foreverfool.com
All three of these healthcare giants are leaders in their niches.
Via The Motley Fool · January 19, 2026
The Trillion-Dollar Pharmacopeia: Eli Lilly’s (LLY) Dominance in the Age of Incretins
As of January 19, 2026, the pharmaceutical landscape is being redefined by a single name: Eli Lilly and Company (NYSE: LLY). Once a steady, century-old stalwart known for its dominance in the insulin market, Lilly has undergone a metamorphosis, evolving into a $1 trillion cardiometabolic powerhouse. The company’s trajectory has been propelled by a class [...]
Via Finterra · January 19, 2026
The New Era of Johnson & Johnson: A 2026 Deep-Dive Research Feature
As of January 19, 2026, Johnson & Johnson (NYSE: JNJ) stands as a radically different enterprise than the one most investors recognized just three years ago. Following the successful spin-off of its consumer health division, Kenvue, JNJ has fully transitioned into a high-growth, pure-play healthcare powerhouse focused exclusively on Innovative Medicine and Medical Technology (MedTech). [...]
Via Finterra · January 19, 2026
Prediction: 2026 Will Be the Year of Eli Lillyfool.com
A catalyst lies just ahead.
Via The Motley Fool · January 19, 2026
Should Investors Worry About Regional Banks After One Firm Dumped 1.8 Million Western Alliance Shares?fool.com
Western Alliance Bancorporation delivers commercial and consumer banking solutions across key western U.S. markets.
Via The Motley Fool · January 18, 2026
This Is My No. 1 Recommended Vanguard ETF to Buy in 2026fool.com
The stars could be aligning for healthcare stocks this year. This Vanguard ETF is a great way to play it.
Via The Motley Fool · January 18, 2026
Could Acquiring Ventyx Biosciences Send Eli Lilly Stock Soaring in 2026?fool.com
The pharmaceutical leader has plenty of cash and is using it effectively.
Via The Motley Fool · January 17, 2026
Why a $6 Million Allocation to Short-Dated Credit Stands Out Right Nowfool.com
The Invesco BulletShares 2026 Corporate Bond ETF targets investment grade U.S. corporate bonds maturing in 2026 with a defined maturity profile.
Via The Motley Fool · January 17, 2026
This Company Is Doubling Down on AI. Is the Stock a Buy?this-com
The pharmaceutical leader continues to grab headlines.
Via The Motley Fool · January 16, 2026
Eli Lilly: A Strong Player in the Pharmaceutical Arenafool.com
Join us as we explore Eli Lilly's impressive market position and financial health. Discover why this pharmaceutical giant is capturing investor attention and what the future may hold for its stock.
Via The Motley Fool · January 16, 2026
The Atomic Revolution: How AlphaFold 3 is Redefining the Future of Medicine
In a milestone that many researchers are calling the "biological equivalent of the moon landing," AlphaFold 3 has officially moved structural biology into a new era of predictive precision. Developed by Google DeepMind and its commercial sister company, Isomorphic Labs—both subsidiaries of Alphabet Inc. (NASDAQ: GOOGL)—AlphaFold 3 (AF3) has transitioned from a groundbreaking research paper [...]
Via TokenRing AI · January 16, 2026
Eli Lilly vs. Novo Nordisk: Which Is the Better Stock Buy?fool.com
The choice isn't that hard.
Via The Motley Fool · January 16, 2026
The $5.1 Trillion Wave: Why 2026 is Set to Become the Biggest Year for Global M&A
As the global economy shakes off the final remnants of the high-interest-rate era, a massive wave of consolidation is sweeping through corporate boardrooms. Analysts have officially adjusted their forecasts for 2026, projecting a staggering $5.1 trillion in total deal volume—a figure that would eclipse the previous records of
Via MarketMinute · January 16, 2026
Nvidia and Eli Lilly Are Partnering on a $1 Billion Lab. Here's What Investors Need to Know.fool.com
The high-powered duo is teaming up to build and equip a $1 billion research facility in California.
Via The Motley Fool · January 16, 2026
Tema ETFs Adds $8 Million to an Industrial Stock Up 63% This Past Yearfool.com
Powell Industries designs and manufactures custom electrical systems for critical infrastructure in heavy industry and utilities worldwide.
Via The Motley Fool · January 16, 2026
Why A 'Solid' First Week For Oral Wegovy Bodes Well For Novo And Lillyinvestors.com
Novo Nordisk's oral Wegovy snagged 3,071 prescriptions in its first week on the market, an analyst said Friday.
Via Investor's Business Daily · January 16, 2026
Eli Lilly Shares Near Highs As Score Flags Momentum Ahead Of Earningstalkmarkets.com
Eli Lilly's stock experiences strong momentum prior to its upcoming earnings report, supported by robust analyst targets and a solid growth narrative, despite recent volatility.
Via Talk Markets · January 16, 2026
Chips and Checks: AI and Banks Lead Wall Street's Chargechartmill.com
Via Chartmill · January 16, 2026